Diarrhea rates increase with dose: 16% at 4 mg, 22% at 8 mg, and 33-34% at 12 mg
It has multiple actions including: potentiation of glucose-mediated insulin secretion mechanisms identified: increased -cell proliferation, resulting in an increase -cell mass (Fusco et al, 2017) stimulation of insulin biosynthesis at the translational level, helping to maintain -cell insulin stores and secretory capacity (Baggio & Drucker, 2007) because the GLP-1 effect is glucose-dependent (there is more insulin release when glucose levels are elevated, but less effect when glucose levels are normal), GLP-1 agonists have a lower risk for producing hypoglycemia compared to sulfonylureas (that chronically stimulate insulin release, independent of glucose concentration) suppression of postprandial glucagon release Evidence indicates that stimulation of pancreatic cells by GLP-1 increases their glucose sensitivity, resulting in less glucagon release at any glucose level (Baggio & Drucker, 2007)
Phase 3 doses are titrated up gradually to a maximum of 12 mg per week
It means that the appetite, energy, and metabolic shifts you once managed with medication now need to be handled through lifestyle and mindful structure
Morning or evening, with or without food
Always store tirzepatide in the refrigerator (36F46F), never in the freezer compartment